---
title: "BUZZ-Cogent Biosciences rises after US FDA agrees to review rare‑disease drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279267495.md"
datetime: "2026-03-16T12:42:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279267495.md)
  - [en](https://longbridge.com/en/news/279267495.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279267495.md)
---

# BUZZ-Cogent Biosciences rises after US FDA agrees to review rare‑disease drug

Shares of drug developer Cogent Biosciences (COGT.O) rise 11.2% to $37.8 premarket Co says the U.S. Food and Drug Administration has accepted to review its experimental drug bezuclastinib for treating patients with a disease known as non-advanced systemic mastocytosis (NonAdvSM)

NonAdvSM is a rare condition where certain immune cells build up in the body more than they should, causing symptoms including skin flushing, stomach issues, tiredness and headaches

COGT says it has received a target action date of December 30 for bezuclastinib

Stock on track to break six-day losing streak if gains hold

As of last close, COGT was down 4.3% YTD

### Related Stocks

- [COGT.US](https://longbridge.com/en/quote/COGT.US.md)

## Related News & Research

- [Cogent Biosciences (COGT) Is Up 6.1% After FDA NDA Filing For Bezuclastinib In GIST](https://longbridge.com/en/news/282325049.md)
- [Cogent Biosciences Stock Falls 6% After Submission Of New Drug Application For Bezuclastinib](https://longbridge.com/en/news/281388189.md)
- [Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial](https://longbridge.com/en/news/282783180.md)
- [RemeGen Drug Approved For Cancer Indication](https://longbridge.com/en/news/282478668.md)
- [GSK posts encouraging data for endometrial and ovarian cancer drug](https://longbridge.com/en/news/282492785.md)